MX2019004299A - Peptidos derivados de fibronectina con bioactividad mejorada y sensibilidad reducida a la degradacion de la elastasa de neutrofilos. - Google Patents

Peptidos derivados de fibronectina con bioactividad mejorada y sensibilidad reducida a la degradacion de la elastasa de neutrofilos.

Info

Publication number
MX2019004299A
MX2019004299A MX2019004299A MX2019004299A MX2019004299A MX 2019004299 A MX2019004299 A MX 2019004299A MX 2019004299 A MX2019004299 A MX 2019004299A MX 2019004299 A MX2019004299 A MX 2019004299A MX 2019004299 A MX2019004299 A MX 2019004299A
Authority
MX
Mexico
Prior art keywords
fibronectin
neutrophil elastase
peptides derived
reduced susceptibility
improved bioactivity
Prior art date
Application number
MX2019004299A
Other languages
English (en)
Inventor
August Clark Richard
Lin Fubao
Original Assignee
Neomatrix Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neomatrix Therapeutics Inc filed Critical Neomatrix Therapeutics Inc
Publication of MX2019004299A publication Critical patent/MX2019004299A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se presentan los polipéptidos derivados de la fibronectina que son resistentes a la elastasa de neutrófilos y pueden unirse a factores de crecimiento y/o aumentar la actividad del factor de crecimiento. Estos polipéptidos son útiles para mejorar la cicatrización de heridas en un paciente.
MX2019004299A 2016-10-14 2017-10-12 Peptidos derivados de fibronectina con bioactividad mejorada y sensibilidad reducida a la degradacion de la elastasa de neutrofilos. MX2019004299A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662408222P 2016-10-14 2016-10-14
PCT/US2017/056399 WO2018071709A1 (en) 2016-10-14 2017-10-12 Peptides derived from fibronectin with improved bioactivity and reduced susceptibility to neutrophil elastase degradation

Publications (1)

Publication Number Publication Date
MX2019004299A true MX2019004299A (es) 2019-12-05

Family

ID=61906459

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019004299A MX2019004299A (es) 2016-10-14 2017-10-12 Peptidos derivados de fibronectina con bioactividad mejorada y sensibilidad reducida a la degradacion de la elastasa de neutrofilos.

Country Status (10)

Country Link
US (2) US11548935B2 (es)
EP (1) EP3526233A4 (es)
JP (1) JP6953537B2 (es)
CN (1) CN110023325B (es)
AU (1) AU2017343752B2 (es)
BR (1) BR112019007563A2 (es)
CA (1) CA3040467C (es)
IL (1) IL266023B2 (es)
MX (1) MX2019004299A (es)
WO (1) WO2018071709A1 (es)

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US860405A (en) 1906-08-27 1907-07-16 Hugh Mcchesley Hoe.
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US5051448A (en) 1984-07-24 1991-09-24 The Mclean Hospital Corporation GABA esters and GABA analog esters
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5166320A (en) 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
JP2594123B2 (ja) 1987-09-12 1997-03-26 株式会社林原生物化学研究所 減感作剤
US5169862A (en) 1989-07-07 1992-12-08 Peptide Technologies Corporation Analogs of viscosin and their uses
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
US5559103A (en) 1993-07-21 1996-09-24 Cytel Corporation Bivalent sialyl X saccharides
US5539085A (en) 1993-08-20 1996-07-23 Onyx Pharmaceuticals, Inc. Bcl-2 and R-ras complex
US5576423A (en) 1994-12-02 1996-11-19 Schering Corporation Antibodies to the slam protein expressed on activated T cells
US6818209B1 (en) 1998-05-22 2004-11-16 Oxford Biomedica (Uk) Limited Retroviral delivery system
US6924123B2 (en) 1996-10-29 2005-08-02 Oxford Biomedica (Uk) Limited Lentiviral LTR-deleted vector
WO2000055335A1 (en) 1999-03-16 2000-09-21 Dana-Farber Cancer Institute, Inc. Pseudotyped lentiviral vectors and uses thereof
WO2000072886A1 (en) 1999-05-26 2000-12-07 Dana-Farber Cancer Institute, Inc. Episomally replicating lentiviral vectors
US7105341B2 (en) 2000-03-06 2006-09-12 Rigel Pharmaceuticals. Inc. In vivo production of cyclic peptides
AU2002340830A1 (en) 2001-05-07 2002-11-18 Tufts University Peptides that bind to dna and inhibit dna replication, and methods of use
US6863884B2 (en) 2002-05-01 2005-03-08 Cell Genesys, Inc. Pseudotyped retroviral vectors
US6799657B2 (en) 2002-10-02 2004-10-05 Carrier Corporation Absorptive/reactive muffler for variable speed compressors
FR2854897B1 (fr) 2003-05-12 2007-05-04 Sederma Sa Compositions cosmetiques ou dermopharmaceutiques pour reduire les signes du vieillissement cutane.
DE602004028250D1 (de) 2003-06-17 2010-09-02 Cognis Ip Man Gmbh Setzungen für hautstraffung
WO2005009510A2 (en) 2003-07-23 2005-02-03 The Regents Of The University Of California Penetration enhancer combinations for transdermal delivery
US20050282747A1 (en) 2003-10-01 2005-12-22 The Research Foundation Of State University Of New York At Stony Brook Methods and compositions for wound healing
EP1755660B1 (en) 2004-05-07 2010-03-24 The University of North Carolina at Chapel Hill Method for enhancing or inhibiting insulin-like growth factor-i
CA2624900A1 (en) * 2005-10-04 2007-04-19 The Research Foundation Of State University Of New York Fibronectin polypeptides and methods of use
WO2008157483A2 (en) * 2007-06-14 2008-12-24 The Research Foundation Of State University Of New York Polypeptides and methods of use
BR112012013035A8 (pt) * 2009-11-30 2018-04-03 Univ Queensland Technology Fibronectina: quimeras do fator do crescimento
WO2015117021A1 (en) * 2014-01-31 2015-08-06 Factor Bioscience Inc. Methods and products for nucleic acid production and delivery

Also Published As

Publication number Publication date
AU2017343752A1 (en) 2019-05-23
CN110023325A (zh) 2019-07-16
US11548935B2 (en) 2023-01-10
EP3526233A4 (en) 2020-03-18
NZ752999A (en) 2022-03-25
CA3040467C (en) 2023-10-31
CN110023325B (zh) 2023-07-04
JP2020500208A (ja) 2020-01-09
US20230331814A1 (en) 2023-10-19
IL266023B1 (en) 2024-03-01
AU2017343752B2 (en) 2021-12-16
IL266023B2 (en) 2024-07-01
BR112019007563A2 (pt) 2019-07-02
WO2018071709A1 (en) 2018-04-19
IL266023A (en) 2019-06-30
US20200223903A1 (en) 2020-07-16
JP6953537B2 (ja) 2021-10-27
CA3040467A1 (en) 2018-04-19
EP3526233A1 (en) 2019-08-21

Similar Documents

Publication Publication Date Title
UY39119A (es) Proteínas de fusión para tratar trastornos metabólicos
AU2019201173B2 (en) Novel polypeptides
NZ718962A (en) Cancer models and associated methods
PH12014501604A1 (en) Polypeptides binding to human complement c5
PH12014502537A1 (en) Therapeutic uses of fibroblast growth factor 21 proteins
HRP20192173T8 (hr) Ekspresija rekombinantnih proteina u kukuljicama vrste trichoplusia ni
HK1208629A1 (en) Hgh-xten fusion protein and its use in the treatment of growth hormone deficiency hgh-xten
MX2020000083A (es) Factor de von willebrand recombinante ( rvwf ) y factor viii recombinante ( rfviii ) para usarse en un metodo para tratar la enfermedad de von willebrand.
HK1215540A1 (zh) 用於治療或預防疾病的因子 蛋白、因子 蛋白及其抑制劑
WO2014004719A3 (en) Chimeric peptide comprising an extracellular matrix protein together with an|antimicrobial peptide for use as a scaffold in wound dressing
WO2015092335A3 (fr) Proteines recombinantes possedant une activite de facteur h
EP3129043A4 (en) Polypeptide compositions with type vii collagen fibronectin type iii- like repeats and treatment methods for wound closure and healing
EP3360895A3 (en) Preparation comprising factor viii and von willebrand factor peptides
ZA201508661B (en) Antifungal plant proteins, peptides, and methods of use
SG11201912799SA (en) Recombinant human-basic fibroblast growth factor (rh-bfgf) and pharmaceutical composition comprising rh-bfgf
AU2018261021A1 (en) Recombinant modified fibroblast growth factors and therapeutic uses thereof
WO2016060918A3 (en) Formulations for histatin therapeutics
SG191060A1 (en) Robo1-fc fusion protein for use in the treatment of hepatocarcinoma
MX2019008529A (es) Peptidos mimeticos de apolipoproteina c-ii (apoc-ii).
WO2014039074A3 (en) Therapeutic compositions and related methods
MX2019004299A (es) Peptidos derivados de fibronectina con bioactividad mejorada y sensibilidad reducida a la degradacion de la elastasa de neutrofilos.
MX2019002497A (es) Peptido con actividad para cicatrizacion de heridas.
EP3290435A4 (en) Peptide having osteoblast differentiation and angiogenesis-promoting activity, and use thereof
EP3280732A4 (en) Antibodies binding to canine vascular endothelial growth factor and uses thereof in treating canine angiogenesis-related diseases
PH12016500509A1 (en) Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins